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Abstract
Objective: To characterize the clinical features and neuropathology associated
with recessive VAC14 mutations. Methods: Whole-exome sequencing was used
to identify the genetic etiology of a rapidly progressive neurological disease pre-
senting in early childhood in two deceased siblings with distinct neuropatholog-
ical features on post mortem examination. Results: We identified compound
heterozygous variants in VAC14 in two deceased siblings with early childhood
onset of severe, progressive dystonia, and neurodegeneration. Their clinical phe-
notype is consistent with the VAC14–related childhood-onset, striatonigral
degeneration recently described in two unrelated children. Post mortem exami-
nation demonstrated prominent vacuolation associated with degenerating neu-
rons in the caudate nucleus, putamen, and globus pallidus, similar to
previously reported ex vivo vacuoles seen in the late-endosome/lysosome of
VAC14-deficient neurons. We identified upregulation of ubiquitinated granules
within the cell cytoplasm and lysosomal-associated membrane protein (LAMP2)
around the vacuole edge to suggest a process of vacuolation of lysosomal struc-
tures associated with active autophagocytic-associated neuronal degeneration.
Interpretation: Our findings reveal a distinct clinicopathological phenotype
associated with recessive VAC14 mutations.
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Introduction
VAC14 is a scaffold protein that complexes with FIG4
and PIKFYVE to regulate biosynthesis of phosphatidyli-
nositol 3,5-bisphosphate (PI(3,5)P2), a signaling lipid that
is important for membrane trafficking of endolysosomal
vesicles.1 Deficiency of PI(3,5)P2 leads to the formation of
large intracellular endolysosomal vacuoles, identifiable by
the presence of late endosomal marker proteins bound to
the membranes of the vacuoles.2,3 In mice, partial or
complete loss of VAC14 causes accumulation of vacuoles
within cells and neurodegeneration.4 Compound
heterozygous variants in VAC14 were recently described
as the cause of childhood-onset striatonigral degeneration
in two unrelated males (MIM:617054),5 however, neu-
ropathologic data were not reported. Here we report the
clinical features and post mortem findings in two siblings
with childhood onset neurodegenerative disease and com-
pound heterozygous variants in VAC14.
Methods
The Royal Children’s Hospital Human Research Ethics Com-
mittee approved the study. Informed consent was obtained
from the patients’ father. Clinical details were obtained from
the deceased patients’ medical records. Exome sequencing of
genomic DNA isolated from fibroblasts from both patients
was carried out at the Australian Genome Research Facility.
Exons were captured using the SureSelect Human All Exon,
V5 + UTRs (Agilent) and sequencing, linkage and variant
analysis was performed as previously described.6
Results
Clinical data
The affected brothers were born to healthy unrelated par-
ents of Anglo-Celtic (paternal) and Anglo-Polish (mater-
nal) descent. The older had an unremarkable perinatal
course and normal development for the first 3 years. At
three and a half years he presented with clumsy walking,
frequent falls, and intention tremor. Within 6 months he
was unable to walk due to dystonia, predominantly affect-
ing his left leg. Dystonia progressed to involve all four
limbs and he developed dysarthria and impaired truncal
balance. One year after symptom onset he developed
painful muscle spasms, joint contractures, and urinary
incontinence. He was treated simultaneously with tri-
hexyphenidyl and a cervical cord stimulator with some
improvement. His dystonia progressed leading to severe
weight loss and death at age 5 years.
The second sibling was born 2 years later. He had nor-
mal motor and cognitive development until age 2 years
when he presented with abnormal movement of his left
leg, slowed walking, and slowed speech. This was followed
by progressive loss of motor function with severe muscle
spasms and dystonia with relative preservation of intellec-
tual capacity. A low-normal level of free gaba-aminobuty-
ric acid (GABA) detected in the CSF led to a trial of
vigabatrin, which dramatically reduced his muscle spasms,
transiently enabling him to stand and walk. The benefit
was not sustained and did not slow the progression of his
motor impairment and dystonia. At age 4 years he had
acute neurological deterioration with vomiting in the set-
ting of fever and died. Both children had normal growth
with head circumferences +1–2 SD from the mean and
no dysmorphic features. Neither child had seizures.
Both children had urine, plasma, and CSF analysis for
evidence of metabolic disease, which were normal. Elec-
troencephalograms for both children were normal. MRI
brain was performed for the first child and was reported as
normal. The images were not available for review. MRI was
not performed for the second child. Electromyography and
nerve conduction studies in the second child were normal.
Genetic studies
Thirty two regions achieved a LOD score of 0.6, the max-
imum score possible using a fully penetrant, recessive
genetic model (Fig. 1). Seventy-one candidate variants
were identified after filtration, which included compound
heterozygous variants in VAC14. VAC14 is relatively
intolerant to functional genetic variation with an RVIS
score of 8.57%.7 Variant 1, NM_018052 c.1271 G>T,
p.Trp424Leu is a very rare missense mutation with only
two heterozygous alleles reported in the gnomAD data-
base in the European (non-Finnish) population. This
variant was reported by Lenk et al.5 as pathogenic when
carried in trans with a splice-site variant. The substitution
affects a highly conserved amino acid located within one
of the heat repeat domains. Variant 2 in the siblings,
NM_018052 c.1096 + 1 G>C is novel and disrupts the
consensus splice-donor site of intron 9. It is absent from
population databases and affects a highly conserved
nucleotide, predicted by in silico tools to cause a frame-
shift and premature stop codon, leading to truncation of
the transcript by more than 50%, therefore leaving it sub-
ject to nonsense-mediated decay (NMD). These variants
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were confirmed by Sanger sequencing of gDNA (Fig. 1).
The c.1096 + 1 G>C variant was paternally inherited. The
children’s mother is deceased and therefore could not be
tested. The effect of the splice-site variant was assessed
using RNA isolated from patient fibroblasts. Sequencing
of the cDNA region spanning the c.1271 G>T,
p.Trp424Leu mutation revealed only the mutant mater-
nally inherited transcript. The paternally inherited allele
encoding the reference G at position c.1271 was not
detectable, consistent with loss of the c.1096 + 1 G>C
allele in the cDNA due to nonsense-mediated decay of
the mRNA (Fig. 2).
Neuropathology
Histology of the brain showed very prominent vacuola-
tion in the neuropil in the caudate nucleus, putamen, and
globus pallidus associated with degenerating neurons
(Fig. 3A). The vacuolation could be seen to extend from
the cell cytoplasm of degenerating neurons showing eosi-
nophilic granular cell cytoplasm (Fig. 3B), immunoreac-
tive with ubiquitin (DAKO) and LAMP2 (Chemicon)
(Fig. 3C–D). A thin LAMP2 immunoreactive membrane
lining the vacuoles was also noted (Fig. 3D). There was
no spheroidal accumulation of neurofilament protein
(DAKO) (not shown). There was a background of minor
gliosis but no inflammatory infiltrate. There was no iron
pigment but focal areas of calcification were seen. There
was no demyelination on luxol fast blue stains and there
were no PAS-positive bodies accumulating. Minor
changes were seen in the pons where similar vacuolation
was seen in the tegmentum. The substantia nigra was well
preserved with no obvious neuronal loss and very sparse
eosinophilic bodies identified. Elsewhere in the cortex,
cerebellum, and brain stem appeared normal with the
exception of occasional eosinophilic bodies in the amyg-
dala, anterior horn, and thalamus. No peripheral nervous
system tissue was available for analysis.
Figure 1. LOD plot. Linkage analysis was performed using SNP genotype calls based on the HapMap database. A recessive genetic model was
applied with a 100% penetrance for homozygous carriers and 0% for heterozygous or homozygous reference samples, with an estimated
population prevalence of 0.001%. This analysis identified several linkage regions genome-wide with a near maximal LOD score (~0.6). The two
VAC14 mutations were within the chromosome 16 linkage region, highlighted in red.
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Discussion
Here we describe for the first time the neuropathological
features of VAC14-associated childhood-onset basal gan-
glia degeneration. VAC14 is a dimeric protein involved in
intracellular vesicle transport through the endolysosome
pathway. It forms a trimolecular complex with FIG4 and
PIKFYVE that regulates biosynthesis of PI(3,5)P2 in the
endosomal membrane. The membrane content of PI(3,5)
P2 is regulated by a dynamic process mediating the gener-
ation and fusion of intracellular transport vesicles. The
tight regulation of PI(3,5)P2 levels is achieved by the
combined action of the lipid kinase PIKFYVE, which syn-
thesizes PI(3,5)P2 from PI3P, and the PI(3,5)P2 phos-
phatase FIG4 that can remove the 5-phosphate, as well as
the scaffold protein VAC14, which stabilizes the protein
complex and may activate PIKFYVE.1,3 Impaired regula-
tion of PI(3,5)P2 levels can result from mutation of any
of these three components of the VAC14 complex.8 The
resultant effect on the endolysosomal pathway manifests
as vacuolation of the cell, which has been observed in
patient fibroblasts9 and brain tissue from mouse mod-
els10,11 and our patients.
The functions of PI(3,5)P2 appear to be critical for neu-
ronal survival. A VAC14-null mouse model demonstrates
extensive neurodegeneration and early lethality with neu-
ronal cell bodies in the CNS that are completely vacuo-
lated.4 A hypomorphic mouse model homozygous for a
missense mutation in VAC14 lives up to 3 weeks and
demonstrates smaller areas of spongiform degeneration in
the brain involving the thalamus, brainstem, and cerebellar
nucleus, which more closely resembles the pathological
changes in our patients.3 It has also been demonstrated that
neurodegeneration in the FIG4 null mouse can be rescued
by the activity of a neuron-specific transgene.11 In our
patients, the cellular vacuolation is seen in the neuritic pro-
cesses rather than the cytoplasm of the CNS neurons and
neurodegeneration is mainly limited to the basal ganglia.
The reason for this localization is not known as VAC14 is
ubiquitously expressed and not GABA specific.
The presence of large apparently empty cytoplasmic
vacuoles lined by LAMP2 suggests a vacuole arising
Figure 2. (A) Pedigree with segregation of two allelic VAC14 variants. (B) Sanger sequencing of the paternally inherited c.1096 + 1 G>C variant.
(C–D) Comparison of genomic DNA and complementary DNA sequencing of the c.1271 G>T variant; Both alleles are detected in the patients’
genomic sequence (C), however, sequencing of the cDNA detected only the allele carrying the c.1271 G>T variant, consistent with loss of the
c.1096 + 1 G>C allele due to nonsense-mediated decay of the mRNA (D).
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within a dilated lysosomal structure. A lack of material
centrally is in keeping with lipid dissolution during the
process of tissue fixation. These findings reflect the
previously reported ex vivo vacuoles seen in the late-
endosome/lysosome of VAC14 deficient neurons.12
Upregulation of ubiquitinated, LAMP-positive granules in
degenerating neurons suggests that the process of massive
vacuolation of lysosomal structures is associated with
active autophagocytic associated neuronal degeneration.
The patients described here are compound heterozy-
gotes carrying one loss-of-function allele and the missense
allele p.Trp424Leu. One of the previously reported
patients also carries the p.Trp424Leu allele in combina-
tion with a different protein truncating mutation. Both
families include Polish ancestry, suggesting that this mis-
sense allele may be enriched in that population.
The two previously reported cases of recessive VAC14-
related childhood-onset neurodegeneration share several
clinical features with our patients. All four affected males had
normal motor and cognitive development prior to onset of
disease in early childhood, between 1.5 and 3 years of age.
Symptom onset was marked by spasticity and dystonia with
relative preservation of cognitive function. The disease course
is rapidly progressive, leading to premature death as early as
2 years after onset. The slightly low GABA levels in the CSF
fluid and positive response to the GABA-ergic anticonvulsant
vigabatrin in one child may reflect destruction of the basal
ganglia and loss of GABA-ergic neurons. Vigabatrin may
therefore be considered for temporary relief of symptoms in
other cases of VAC14-related neurodegerative disease.
The patients reported by Lenk et al.5 have signal abnor-
malities in the striatum and substantia nigra on susceptibility
Figure 3. Neuropathology. (A) Marked vacuolation in the caudate nucleus (CN) and putamen (P), with unremarkable internal capsule (IC).
Hematoxylin and Eosin 9 4. (B) Vacuoles present in the neuropil could sometimes be seen to extend from the cell body (arrow). Degenerating
granular eosinophilic neurons were seen (circles). Putamen, Hematoxylin, and Eosin 9 400. (C) Vacuoles showed a fine ubiquitin immunoreactive
rim (circle). Granular dense ubiquitin was present in degenerating neurons (arrow). Putamen, ubiquitin immunoperoxidase 9 400. (D) Vacuoles
within the putamen were lined by LAMP2 immunoreactive membrane (circle). LAMP 2 granular bodies were present in cytoplasmic bodies
(arrow). Putamen, LAMP2 immunoperoxidase 9 400.
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and diffusion-weighted images. Our patient had MRI prior
to the availability of these sequences and it was reported as
normal. Although our patient’s MRI is not available for
comparison, neither of our patients showed histological
abnormalities in the substantia nigra. Evidence of nigral
involvement is therefore not an essential feature of this dis-
ease.
Conclusion
VAC14 is essential for vesicular trafficking in the endolyso-
somal pathway. Deficiency of this protein leads to vacuola-
tion of the neuropilin in the brain, particularly the basal
ganglia. Biallelic VAC14 mutations cause a distinctive phe-
notype of childhood-onset progressive dystonia that is
symptomatic of the underlying basal ganglia degeneration.
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